# Data Sheet (Cat.No.T39105)



## Ibiglustat succinate

Chemical Propert	ties	
CAS No. :	1629063-80-4	
Formula:	C24H30FN3O6S	
Molecular Weight:	507.58 e Hold Hold Hold Hold Hold Hold Hold Hold	H <sub>3</sub> C CH <sub>3</sub>
Appearance: 🦲	no data available	s'
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year	, Second Se Second Second Seco

### **Biological Description**

Description	Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant inhibitor of glucosylceramide synthase (GCS). It is utilized in the investigation of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
In vitro	Ibiglustat succinate (SAR402671) administered at 1 µM for 15 days to Fabry disease (FD) cells results in GL-3 levels nearly equivalent to those in untreated wild-type (WT) cells, indicating its potential to halt further GL-3 accumulation and mitigate excessive sphingolipid levels in FD cardiomyocytes[4].

Preparing Stock Solutions			
	1mg	5mg	10mg
1 mM	1.9701 mL	9.8507 mL	19.7013 mL
5 mM	0.394 mL	1.9701 mL	3.9403 mL
10 mM	0.197 mL	0.9851 mL	1.9701 mL
50 mM	0.0394 mL	0.197 mL	0.394 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

#### Reference

Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945. Published 2021 Oct 22.

#### Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481